A tiny fish could end painful metabolic and genetic bone diseases

Reviewed by James Ives, M.Psych. (Editor)Jul 15 2020

In a study published recently in Communications Biology, researchers led by Kanazawa University explain how a tiny fish could help end painful metabolic and genetic bone diseases.

While pain, swelling, and immobility are the most obvious aftereffects of a broken bone, there is also a flurry of activity going on at the cellular level in an effort to repair the damage. And because bones are usually hidden away under layers of muscle, fat, and skin, it has been difficult for researchers to study in real time how bones regenerate.

To provide insight into the process of fracture repair, we needed bone that was easily accessible and a model species in which bone growth mimicked that of humans. With transgenic and mutant lines already available, zebrafish scales ticked all the boxes."

Jingjing Kobayashi-Sun, Study Lead Author, Kanazawa University

Zebrafish scales, although much simpler than mammalian bones, respond and develop in almost the same way as their more complex counterparts, and are conveniently located on the outside of the body. Most importantly though, they contain both osteoclasts and osteoblasts, the cells that respectively clear away broken bone fragments and generate new bone after a fracture.

Explains Kobayashi-Sun, "Recent studies have suggested that molecular packages, called extracellular vesicles (EVs), derived from osteoblasts may deliver signaling molecules to immature osteoclasts, triggering their differentiation into mature, active cells. However, given the difficulty of live imaging in bone, no one has been able to prove this process actually occurs in vivo."

To visualize osteoblasts and osteoclasts in zebrafish scales, the researchers generated a double transgenic line in which the two cell types expressed different color fluorescent labels.

After making small cuts in the scales of anesthetized fish, the researchers could identify the different cell types in the healing bone using a fluorescent microscope or flow cytometry.

"We observed that a large number of the green fluorescent osteoclasts at the fracture site contained red fluorescent osteoblast-derived particles in the cytoplasm, confirming the uptake of EVs by immature osteoclasts," says senior author Isao Kobayashi. "In addition, mature osteoclasts were abundant in the damaged scales, indicating that EV uptake triggers the differentiation of osteoclasts."

The EVs contained high levels of a cellular differentiation-associated signaling molecule called RANKL. Knocking out the corresponding gene resulted in a significant reduction in the number of osteoclasts, suggesting that osteoblasts control osteoclast formation via Rankl signaling.

Given that many bone disorders result from a breakdown in communication between osteoblasts and osteoclasts, these findings provide valuable information for the development of novel drug therapies.